Outcomes of breast cancer patients with an ultralow-risk 70-gene signature in the MINDACT trial

Patients with 70-gene signature ultralow-risk breast cancers have shown excellent survival in historic cohorts, including randomized trials. This subgroup was characterized to help avoid overtreatment in early-stage breast cancer. In the prospective MINDACT trial, the largest cohort to date, patients with ultralow risk 70-gene signature had an 8-year breast cancer-specific survival of 99%, regardless of clinical risk, and their risk of distant metastatis or breast cancer-related death was significantly lower compared to patients with low-risk tumors. The authors conclude that the 70-gene signature ultralow risk could be used in future trials investigating the de-escalation of endocrine therapy to better balance benefits and harms.